Join experts Drs Matthew Sparks and James Matthew Luther as they discuss how and why they're using mineralocorticoid receptor antagonists to treat patients with diabetic kidney disease in their practice.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/991189). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Chronic Kidney Disease (CKD) https://emedicine.medscape.com/article/238798-overview
Physiology, Aldosterone https://www.ncbi.nlm.nih.gov/books/NBK470339/
Angiotensin II https://www.ncbi.nlm.nih.gov/books/NBK499912/
Primary Aldosteronism https://emedicine.medscape.com/article/127080-overview
Epithelial Sodium Channel (ENaC) and the Control of Blood Pressure https://pubmed.ncbi.nlm.nih.gov/24721652/
Hypertension Treatment & Management https://emedicine.medscape.com/article/241381-treatment
Hypertension Medication https://emedicine.medscape.com/article/241381-medication#2
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease - Mechanistic and Therapeutic Effects https://pubmed.ncbi.nlm.nih.gov/34675379/
Malignant Hypertension https://emedicine.medscape.com/article/241640-overview
Androgenetic Alopecia https://emedicine.medscape.com/article/1070167-overview
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/33264825/
Cardiovascular Events With Finerenone in Kidney Disease and Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/34449181/
Regression to the Mean https://www.britannica.com/topic/regression-to-the-mean
Sodium-glucose Transport Protein 2 (SGLT2) Inhibitors https://www.ncbi.nlm.nih.gov/books/NBK576405/
Potassium Binders for Chronic Hyperkalaemia in People With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/32588430/